SUNNYVALE, Calif. — Cepheid (Nasdaq: CPHD) today announced the release of its improved Xpert(R) BCR-ABL Monitor test to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. With improved time-to-results, the test now detects the BCR-ABL chromosomal translocation in about 2 hours...
Latest News
It is possible to determine which patients run a high risk of developing Alzheimer’s disease and the dementia associated with it, even in patients with minimal memory impairment. This has been shown by recent research at the Sahlgrenska Academy, University of Gothenburg, Sweden. The results have been published in the...
SAN DIEGO — Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson’s disease. CERE-120 uses AAV-based gene therapy to deliver the neurotrophic factor, neurturin, to Parkinson’s disease patients in order to restore the function and protect degenerating...
CAMBRIDGE, Mass. — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neurological diseases, today announced positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon, the first and only D1/D5 receptor partial agonist being studied as a once-daily treatment for...
SOUTH SAN FRANCISCO, Calif. – Cero Therapeutics Holdings, Inc., (NASDAQ:CERO) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms today announced the publication in Clinical Cancer Research, a journal of the American Association for Cancer Research, a paper titled “Therapeutic...
MELBOURNE, Australia — Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (Systemic scleroderma), having previously...
DUBLIN, Ireland— The “Cervical Intraepithelial Neoplasia – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering. The “Cervical Intraepithelial Neoplasia – Pipeline Insight, 2023” report offers a comprehensive overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape, featuring insights into more than 8 companies and over 10 pipeline drugs....
BOSTON, Mass. — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an oral small molecule drug candidate targeting critical disease processes underlying degenerative disorders of the brain, has been selected for inclusion in the EXPERTS-ALS platform. EXPERTS-ALS facilitates rapid testing...
BETHESDA, Md. – Today, the Cystic Fibrosis Foundation announced three new research awards as part of its Path to a Cure initiative to accelerate the development of treatments for the underlying cause of cystic fibrosis for every person with the disease. The latest round of funding includes up to $2.6 million to...
BETHESDA, Md. – Today, the CF Foundation announced a new collaboration with venture creator Deep Science Ventures, focused on uncovering and designing new technologies with the potential to overcome challenges to developing genetic therapies for cystic fibrosis. The collaboration is part of the Foundation’s $500 million Path to a Cure to accelerate...